Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Cancer Immunology, Immunotherapy
Published in: Cancer Immunology, Immunotherapy 2-3/1999

01-06-1999 | ORIGINAL ARTICLE

Homing of intravenously and intralymphatically injected human dendritic cells generated in vitro from CD34+ hematopoietic progenitor cells

Authors: Andreas Mackensen, Thomas Krause, Uli Blum, Peter Uhrmeister, Roland Mertelsmann, Albrecht Lindemann

Published in: Cancer Immunology, Immunotherapy | Issue 2-3/1999

Login to get access
Metadata
Title
Homing of intravenously and intralymphatically injected human dendritic cells generated in vitro from CD34+ hematopoietic progenitor cells
Authors
Andreas Mackensen
Thomas Krause
Uli Blum
Peter Uhrmeister
Roland Mertelsmann
Albrecht Lindemann
Publication date
01-06-1999
Publisher
Springer-Verlag
Published in
Cancer Immunology, Immunotherapy / Issue 2-3/1999
Print ISSN: 0340-7004
Electronic ISSN: 1432-0851
DOI
https://doi.org/10.1007/s002620050555

Other articles of this Issue 2-3/1999

Cancer Immunology, Immunotherapy 2-3/1999 Go to the issue

ORGINAL ARTICLE

In vitro analysis of the melanoma/endothelium interaction increasing the release of soluble intercellular adhesion molecule 1 by endothelial cells

ORIGINAL ARTICLE

Study of HLA class I restriction and the directed antigens of cytotoxic T lymphocytes at the tumor sites of ovarian cancer

ORIGINAL ARTICLE

The role of interleukin-2 in regulating the sensitivity of natural killer cells for Fas-mediated apoptosis

ORIGINAL ARTICLE

Granulocyte/macrophage-colony-stimulating factor released by adenovirally transduced CT26 cells leads to the local expression of macrophage inflammatory protein 1α and accumulation of dendritic cells at vaccination sites in vivo

ORIGINAL ARTICLE

Neuronal autoantibody titers in the course of small-cell lung carcinoma and platinum-associated neuropathy

ORIGINAL ARTICLE

Increased generation of autologous tumor-reactive lymphocytes by anti-CD3 monoclonal antibody and prothymosin α
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits